<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">Specific drugs for SARS-CoV-2 are obviously not available. Currently, drugs originally developed for HIV (e.g. lopinavir, ritonavir) are under evaluation on the basis of weak evidences from retrospective analyses suggesting clinical benefit in the treatment of the two previous coronavirus epidemics [
 <xref ref-type="bibr" rid="CR6">6</xref>]. Similarly, anti-malaria chloroquine or hydroxychloroquine are tested [
 <xref ref-type="bibr" rid="CR7">7</xref>]. The inhibitor of Influenza’s polymerase Favipiravir is currently evaluated in a clinical trial in combination with anti-IL-6 receptor Tocilizumab (NCT04310228). Finally, the inhibitor of Ebolavirus’ polymerase Remdesivir is currently evaluated in two major SIMPLE clinical trials (NCT04292899; NCT04257656) [
 <xref ref-type="bibr" rid="CR8">8</xref>]. On Apr. 29, 2020 it was announced that results from the trial NCT04292899 showed clinical improvement for 50 percent of patients in 10 days in the 5-day treatment group and 11 days in the 10-day treatment group (
 <ext-link ext-link-type="uri" xlink:href="https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19</ext-link>). However, a trial conducted in China showed Remdesivir did not improve patients’ condition nor reduced the positivity to virus. Moreover, the drug showed also significant side effects (
 <ext-link ext-link-type="uri" xlink:href="https://www.ft.com/content/0a4872d1-4cac-4040-846f-ce32daa09d99" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ft.com/content/0a4872d1-4cac-4040-846f-ce32daa09d99</ext-link>).
</p>
